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Introduction
Acute graft-versus-host disease (GVHD) is the most serious 
complication of allogeneic BM transplantation (BMT) and was 
noted in animal models more than 6 decades ago (1, 2). Acute 
GVHD predominantly involves the skin, liver, and lower gastro-
intestinal (GI) tract (3).
Without rigorous depletion of donor T cells from the graft, this 
complication occurs in 30%–70% of patients after allogeneic BMT 
(4–6). Standard treatment of acute GVHD is the administration 
of systemic corticosteroids and additional immunosuppressive 
agents; only half of patients who develop acute GVHD will have 
a complete response to corticosteroid therapy, although the num-
bers vary widely between studies (7). The outcome for patients 
with severe GVHD of the lower GI tract is poor, with 25% overall 
survival (8). We undertook this study to understand the biologic 
role of regenerating islet-derived 3α/γ (REG3α/γ) in GI GVHD.
Results
An elevated REG3α blood level is a strong indicator of GI GVHD 
that drives transplant reported mortality (9–12). We observed that 
increased blood levels of REG3α in patients with GVHD inverse-
ly correlated with the number of Paneth cells (Figure 1, A–C) 
and observed a similar inverse correlation in 2 mouse models of 
GVHD (Figure 1, D–I, and Supplemental Figure 1; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI99261DS1). This inverse correlation continued over time and 
increased with GVHD severity independently of BMT condition-
ing (Figure 2). IL-22 induces REG3γ (13–15), and the production of 
IL-22 decreased very rapidly during GVHD (Figure 2). Increased 
Reg3g expression was not observed in any other tissue, including 
lung, liver, and pancreas (data not shown), suggesting that dam-
age to the GI crypt resulted in the loss of REG3γ into the systemic 
circulation. REG3α serum levels remained elevated, often by an 
order of magnitude, after 1 week of systemic steroid therapy in 
patients with GI GVHD and predicted increased nonrelapse mor-
tality, confirming the significance of continued serum elevations 
with respect to long-term clinical outcomes (Figure 3 and ref. 16).
We next investigated the role of REG3γ in GVHD using 
REG3γ-deficient (Reg3g−/−) mice as BMT recipients. Reg3g−/− mice 
experienced more severe clinical GVHD and greater mortality 
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Defa1, Defa2, S100a8, and S100a9, did not consistently change in 
Reg3g−/− recipients (Supplemental Figure 11).
To investigate the effect of REG3γ on intestinal stem cells 
(ISCs), we bred Reg3g−/− mice with mice heterozygous for green 
fluorescent protein (GFP) in Lgr5+ enterocytes (20) to use as BMT 
recipients. We confirmed that the loss of ISCs during GVHD (21) 
was not reversed by IL-22 treatment in Reg3g−/− mice (Figure 8A and 
Supplemental Figure 12). We next quantified ISC apoptosis and pro-
liferation using established flow cytometry protocols (22). Surpris-
ingly, IL-22 did not affect ISC proliferation under any conditions, 
but reversed apoptosis only in WT and not in Reg3g−/− recipients; 
the number of ISCs correlated directly with Reg3g mRNA expres-
sion (Figure 8, B–D, and Supplemental Figures 13 and 14). We then 
directly evaluated the antiapoptotic properties of REG3α in intes-
tinal epithelium in vitro. Addition of REG3α in vitro to colonic epi-
thelial cell lines undergoing apoptotic stress reduced the cleavage 
of caspase-3, caspase-8, and PARP and increased cell viability in a 
dose-dependent manner, confirming its role as a survival factor for 
epithelial cells (Figure 8, E–G, and Supplemental Figure 15).
Discussion
We report here that the production of REG3α/γ in the GI tract falls 
as acute GVHD progresses and inversely correlates with its con-
centration in the serum, supporting the concept of this biomarker 
as a “liquid biopsy” that quantifies crypt damage and the loss of 
than WT mice in 2 GVHD models (Figure 4, A–C). The histologic 
severity of GVHD, as measured by Paneth cell apoptosis and loss, 
also increased in Reg3g−/− BMT recipients; so did the number of 
crypt cells expressing cleaved caspase-3, a hallmark of apoptosis 
(Figure 4, D–F, and Supplemental Figures 2 and 3). Reg3g−/− alloge-
neic BMT recipients also exhibited significantly more CD8+ IFN-γ+ 
effector T cells in the lamina propria as well as increased hepatic 
infiltrates, confirming greater histologic damage in the absence of 
recipient REG3γ (Supplemental Figures 3 and 4). The composition 
of fecal microbial communities did not differ significantly, howev-
er, between WT and Reg3g−/− BMT recipients either before trans-
plant or during GVHD (Figure 4, G–I, and Supplemental Figure 5).
Although IL-22 has pleiotropic effects and can increase GVHD 
severity in some models (17, 18), prophylactic administration of 
IL-22 prevented GVHD and increased REG3γ production in the 
ileum as previously reported (15) while simultaneously decreasing 
serum REG3γ levels (Figure 5 and Supplemental Figure 6). IL-22 
treatment of mice also reversed established GVHD in 2 separate 
models, and decreased release of REG3γ into serum (Figure 6 and 
Supplemental Figure 7). IL-22 was completely unable, however, 
to prevent clinical and histologic GVHD and Paneth cell loss in 
Reg3g−/− recipients in 2 separate models, confirming the need for 
REG3γ to repair the integrity of GI epithelium (Figure 7 and Sup-
plemental Figures 8–10). mRNA expression of other antimicrobial 
Paneth cell proteins that are disrupted during GVHD (19), such as 
Figure 1. REG3α/γ levels in the plasma/serum and intestinal 
mucosa during GVHD. (A–C) Samples were collected from 28 
allogeneic BMT patients without GVHD (white circles, n = 13) 
and with GVHD (black circles, n = 15). (A) Plasma concentra-
tions of REG3α measured by ELISA. (B) Average Paneth cell 
numbers per high-power field (HPF) in the same biopsies. (C) 
Semiquantitative REG3α expression in the duodenum. (D–F) 
B6 mice underwent BMT from syngeneic B6-Ly5.1 donors 
(GVHD –, white circles, n = 7) or allogeneic C3H.SW donors 
(GVHD +, black circles, n = 7), and samples were analyzed 
on day +7 after BMT. (D) Serum REG3γ levels measured by 
ELISA. (E) Average Paneth cell numbers per HPF in ileal tissue 
from the same mice. (F) Ileal tissue Reg3g mRNA expression 
measured by quantitative PCR (qPCR). (G–I) B6D2F1 mice 
underwent BMT from syngeneic B6D2F1 donors (GVHD –, 
white circles, n = 6) or allogeneic B6 donors (GVHD +, black 
circles, n = 6), and samples were analyzed as before on day +7 
after BMT. (G) Serum REG3γ levels. (H) Average Paneth cell 
numbers per HPF in ileal tissue. (I) Ileal tissue Reg3g mRNA 
expression. **P < 0.01, unpaired 2-tailed t test. Data are 
expressed as mean ± SEM.
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nificantly increased the loss of ISCs and Paneth cells. This dis-
crepancy suggested that the antimicrobial activity of REG3γ was 
not primarily responsible for its protective properties. Absence of 
host REG3γ thus amplified GVHD by accelerating apoptosis of the 
crypts, allowing microbes to break the mucosal epithelial barrier 
and activate antigen-presenting cells that attracted and stimu-
lated alloreactive donor T cells, furthering crypt damage (27).
Previous experiments with cultured pancreatic acinar cells 
and hepatocytes suggested that expression of REG3β could 
reduce the apoptosis mediated by TNF-α, an important media-
tor of GVHD (28, 29). Our results directly demonstrate a survival 
function for REG3α/γ that is key to restoration of epithelial integ-
rity during GVHD. A recently published approach to GVHD pre-
vention is the promotion of Paneth cell development from ISCs 
through the administration of R-spondin-1, a Wnt agonist (30). 
It is unknown whether R-spondin-1 requires REG3γ to increase 
Paneth cell number as does IL-22. In this regard it is interesting 
to note that although IL-22 increases ISC number in vivo and 
stimulates organoid growth in vitro, it does not act as a mito-
ISCs and Paneth cells. Administration of IL-22 restores GI epitheli-
al integrity and reduces GVHD because REG3α/γ acts as a survival 
signal for ISCs and Paneth cells, preventing their apoptosis both in 
vitro and in vivo. The requirement of REG3α/γ to repair damaged 
GI epithelium treatment indicates a previously unknown function 
for this protein in GI crypt homeostasis.
These results suggest the possibility of a more physiologic 
approach to the prevention and treatment of GI GVHD through 
restoration of the GI mucosal barrier rather than intensified sys-
temic immunosuppression. Paneth cells, the “guardians of the 
crypt,” secrete multiple antimicrobial peptides, including REG 
proteins, that help to generate the chemical/physical barrier of the 
GI mucosa (23). A disrupted microbiome constitutes a significant 
risk factor for both experimental and clinical GVHD (24, 25) and 
might amplify GVHD by exposing enterocytes to Gram-positive 
pathogens (26). But analysis of the fecal microbiome demonstrat-
ed that the absence of REG3γ produced no significant difference 
in the microbial community architecture either before or during 
GVHD even though it caused greater crypt destruction and sig-
Figure 2. Time course of REG3γ and IL-22 expression during GVHD. (A–C) B6D2F1 mice underwent BMT from syngeneic B6D2F1 donors (no GVHD, white 
circles) or allogeneic B6 donors (GVHD, black or blue circles), and samples were analyzed on days +3, +7, and +14 after BMT (n = 5 for each group on each 
day). (A) Serial REG3γ levels in the serum as measured by ELISA. (B) Serial average Paneth cell numbers per HPF in ileal tissue. (C) Serial Reg3g and IL-22 
mRNA expression in the ileum was measured by qPCR. (D–G) B6D2F1 mice underwent BMT, without irradiation conditioning, from syngeneic B6D2F1 
donors (no GVHD, white triangles) or allogeneic B6 donors (GVHD, black triangles). (D–F) Serial body weight measurement (D), clinical GVHD score (E), 
and survival (F) of mice after BMT. (G) Serial Reg3g mRNA expression in the ileum on days +3, +7, and +14 after BMT (n = 6 for each group on each day). 
*P < 0.05, **P < 0.01, unpaired 2-tailed t test (A–E and G); **P < 0.01, log-rank test (F). (H–K) Following irradiation, B6 mice received 5.0 × 106 BM cells 
plus 0 × 106 to 5.0 × 106 T cells, as indicated, from C3H.SW donors. Samples were analyzed on day +7 after BMT (n = 4 for each group). (H) Body weight 
measurement. (I) Clinical GVHD score. (J) Serum REG3γ levels. (K) Reg3g mRNA expression in the ileum. *P < 0.05, **P < 0.01, 1-way ANOVA. Data are 
expressed as mean ± SEM.
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without GVHD had a histologic grade of 0, and the median time of 
biopsy was day +37 (range 15–78); all those with GVHD had a histologic 
grade of 3, and the median time of biopsy was day +65 (range 13–138).
Mice. C57BL/6 (B6; H-2b, CD45.2+), B6-Ly5.1 (H-2b, CD45.1+), B6 
× DBA2 F1 (B6D2F1; H-2b/d), and BALB/c (H-2d, CD90.2+) mice were 
purchased from Charles River Laboratories. C3H.SW (H-2b, CD45.2+) 
mice were purchased from The Jackson Laboratory. Reg3g−/− (H-2b) 
mice were obtained from Lora V. Hooper (26). B6-Lgr5-EGFP-IRES-
creERT2 (Lgr5-EGFP+) mice were a gift from Linda C. Samuelson (Uni-
versity of Michigan, Ann Arbor, Michigan, USA). Reg3g−/− mice were 
bred with WT Lgr5-EGFP+ mice to generate dual Reg3g−/−/Lgr5-EGFP+ 
mice (B6 background). For BMT experiments, WT and Reg3g−/− recipi-
ent mice were cohoused for a minimum of 2 weeks, in order to reduce 
heterogeneity in the microbiota between the strains. All animals were 
cared for under the regulations reviewed and approved by the Univer-
sity Committee on the Use and Care of Animals, per University Labo-
ratory Animal Medicine guidelines at the University of Michigan or the 
Icahn School of Medicine at Mount Sinai.
BMT. BMT was performed as previously described (32, 33). Brief-
ly, BM cells were collected from the femurs and tibiae of euthanized 
donor mice. Donor T cells were obtained from the spleens of donor 
mice by positive selection using CD90.2 magnetic beads (Miltenyi 
Biotec), according to the manufacturer’s instructions. Unless other-
wise stated, B6D2F1 recipients were given a total of 1,250 cGy total-
body irradiation, split into 2 doses separated by 4 hours on day –1, and 
then injected with 2 × 106 to 4 × 106 splenic T cells and 5 × 106 BM 
cells from allogeneic B6 donors on day 0. B6 recipients were irradi-
ated with 1,100 cGy total-body irradiation, as a single dose on day 
–1, and injected on day 0 with 50 × 106 whole splenic cells and 5 × 
106 BM cells from MHC-matched, minor antigen–disparate C3H.SW 
donors or 5 × 106 whole splenic cells and 5 × 106 BM cells from MHC- 
mismatched BALB/c donors.
gen as was initially thought; rather it prevents the apoptosis (or 
necroptosis) caused by the inflammation of GVHD through the 
induction of REG3γ. Thus, in addition to its well-defined anti-
microbial properties, REG3γ provides critical survival signals to 
cells in the stem cell niche.
The potential limitations of this study should be noted. First, 
the mechanistic insights derive from mouse models and cell lines 
that cannot reproduce the complexity of human disease. Despite 
many tight correlations between human and murine data, some 
experiments do not and cannot have precise human equivalents, 
e.g., quantification of ISCs through a green fluorescent protein. 
Another important limitation relates to differences along the axi-
al geography of the bowel. Both the large and the small intestine 
contain Lgr5+ ISCs, but Paneth cells are largely absent in the colon, 
where the stem cell niche is supported by deep secretory cells that 
possess some similarities to Paneth cells (31). Experiments are 
currently in progress to determine whether REG3γ also acts as a 
survival signal for colonic ISCs in vivo. If restoration of the survival 
signal provided by REG3γ can repair damaged intestinal epitheli-
um of both small and large intestines, this approach may offer a 
novel, nonimmunosuppressive strategy not only for GVHD but for 
other immunologically mediated diseases of the bowel.
Methods
Patients. Patients were studied with the approval of the Institutional 
Review Boards at the University of Michigan, and all patients gave writ-
ten informed consent in accordance with the Declaration of Helsinki. 
Twenty-eight patients, who consented to a prospective observational 
trial of allogeneic BMT complications and underwent allogeneic BMT 
from 2002 to 2007, were available for analysis; samples were obtained 
from patients who developed GI symptoms and had a duodenal biopsy 
and plasma collection at the time of onset of symptoms. All patients 
Figure 3. Serum REG3α levels and correlates with 
nonrelapse mortality in patients with GI GVHD. Patients 
with GI GVHD (n = 145) who were treated with systemic 
steroids for at least 7 days provided blood samples for 
biomarker analysis and were divided according to bio-
marker probabilities into low (blue) and high (pink) groups 
as previously published (16). Twelve-month nonrelapse 
mortality and REG3α serum levels are shown for test  
(n = 71) (A) and validation (n = 74) (B) cohorts. **P < 0.01, 
unpaired 2-tailed t test. Data are expressed as box-and-
whisker plots.
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To investigate the effect of treatment with IL-22 after development 
of GVHD, mice received i.p. injections of 10 μg of IL-22 in PBS, or PBS 
as a control, starting on day +7 after BMT. Mice were given either 3 daily 
doses (when GI tissues were analyzed on day +10) or a total of 7 total 
doses on days 7, 8, 9, 11, 13, 15, and 17 (for longer-term GVHD studies).
All animals were individually ear-tagged before BMT (4 animals per 
cage). At the time of randomization to receive IL-22 or PBS alone (day 0 
for prophylaxis experiments and day 7 for treatment experiments), the 
first 2 mice were assigned to the IL-22 group and the second 2 mice were 
assigned to the PBS group. For experiments evaluating treatment begin-
ning on day 7, animals with severe GVHD (weight loss of more than 
In all experiments, transplantation with cells from the appropriate 
syngeneic donor or BM only was used as a control. Donor and recipi-
ent mice were sex-matched and were 8–16 weeks of age at the time of 
transplantation. Survival was monitored daily, and clinical GVHD was 
assessed weekly by a previously described scoring system (34).
Administration of IL-22 in vivo. Recombinant mouse IL-22 (carrier- 
free) was purchased from BioLegend. For prophylaxis experiments, 
mice received i.p. injections of 10 μg of IL-22 in PBS, or PBS as a con-
trol, on alternate days from day +1 after BMT. Mice were given either 3 
doses (when GI tissues were analyzed on day +7) or 6 doses (for longer- 
term assessment of GVHD scores and survival).
Figure 4. REG3γ absence increases GVHD severity. WT B6 and B6-Reg3g–/– (KO) mice underwent BMT from B6-Ly5.1 donors (GVHD –: WT, white 
circles; KO, white squares) or C3H.SW donors (GVHD +: WT, black circles; KO, red squares). (A–C) Serial body weight measurement (A), clinical GVHD 
score (B), and survival (C) of mice after BMT (WT, white circles, n = 7; KO, white squares, n = 7; WT, black circles, n = 18; KO, red squares, n = 16). (D–F) 
On day +7 after BMT, WT or KO recipients (Lgr5-EGFP+) were euthanized. Small intestine crypt cells were isolated and analyzed by flow cytometry. 
Small intestine sections were stained by immunochemistry. (D and E) Quantification of Paneth cells (D) and quantification of Paneth cells undergo-
ing early apoptosis by annexin V+ staining (E) (WT, white circles, n = 6; KO, white squares, n = 6; WT, black circles, n = 8; KO, red squares, n = 8). (F) 
Quantification of cleaved caspase-3+ cells per crypt of ileum sections in recipients (each group, n = 5). *P < 0.05, **P < 0.01, ***P < 0.001, unpaired 
2-tailed t test (A, B, and D–F); **P < 0.01, log-rank test (C). Data are expressed as mean ± SEM. (G–I) Microbiome composition of fecal samples from 
WT and KO mice 1 day before BMT (Pre-BMT) (WT, white circles, n = 12; KO, white squares, n = 13) or day +7 after BMT (Post-BMT) (WT, black circles, 
n = 12; KO, red squares, n = 13). (G) Principal component analysis was computed from the Bray-Curtis β-diversity matrix among all samples. (H and I) 
Bray-Curtis compositional distances were measured from the centroid of WT pre-BMT samples (H) or post-BMT samples (I). NS, P > 0.05; *P < 0.05, 
**P < 0.01, Wilcox test.
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25%) were excluded before randomization. This criterion was estab-
lished before BMT and the subsequent development of disease.
5-Ethynyl-2′-deoxyuridine incorporation in vivo assay. ISC prolifer-
ation was determined using 5-ethynyl-2′-deoxyuridine (EdU) incor-
poration into DNA. Lgr5-EGFP+ mice were injected i.p. with 200 
μl of 5 mM EdU solution (Invitrogen) in PBS 2 hours before small- 
intestinal samples were collected. EdU was detected with the Click-iT 
Plus EdU Flow Cytometry Assay kit according to the manufacturer’s 
instructions (Invitrogen).
Histopathology and immunohistochemistry. For pathologic analy-
ses, samples from patients (duodenal biopsies) and mice (distal ilea 
and livers) were fixed in 10% neutral-buffered formalin, embedded in 
paraffin, sectioned, slide-mounted, and stained with H&E (12). Paneth 
cells were identified by their eosinophilic granules by an experienced 
observer blinded to the treatment groups, in at least 3 high-power 
fields (HPFs) with an Olympus BX51 microscope. Using a highly repro-
ducible technique (12), HPF was defined as a ×40 objective with a field 
of 0.345 mm2. The counts from each HPF were averaged to give the 
number of Paneth cells per HPF.
Immunohistochemistry was performed with polyclonal rabbit anti-
REG3α (Abcam, ab134309) at a 1:200 dilution for human samples and 
rabbit anti-REG3γ from the Lora V. Hooper laboratory (26) at a 1:8,000 
dilution or rabbit anti–cleaved caspase-3 (clone 5A1E, Cell Signaling) at 
a 1:400 dilution for murine samples using a DAKO AutoStainer Link; 
slides were subsequently coated with a goat anti-rabbit IgG HRP conju-
gate (DAKO) at a 1:200 dilution and finally a diaminobenzidine (DAB) 
dilution to generate brown-colored signals. Slides were counterstained 
with Harris hematoxylin. Semiquantitative REG3α expression from 
duodenum biopsies was scored on a 0–2 scale for 3 parameters: Paneth 
cells, epithelial cytoplasm, and stromal cells. Pictures from tissue sec-
tions were taken using a digital camera (DP70, Olympus) mounted on 
a microscope (BX51, Olympus) or an EVOS XL Core Imaging System 
from Life Technologies.
Quantitative PCR. Total RNA was isolated from the small intestine 
using the RNeasy RNA Isolation Kit (Qiagen) and was used to synthesize 
cDNA with the High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). Quantitative PCR analysis was performed using the SYBR 
Green Master Mix (Invitrogen) and specific primers. Signals were nor-
malized to Gapdh levels within each sample, and normalized data were 
used to calculate relative levels of gene expression using ΔΔCt analysis. 
Details of all primers used can be found in Supplemental Table 1.
ELISA. REG3α in human plasma was quantified with the REG3α 
ELISA kit (MBL International, Japan) as described previously (11). 
REG3γ in mouse serum was measured by a REG3γ ELISA Kit (Cloud-
Figure 5. Prophylactic administration of IL-22 reduces GVHD. B6D2F1 mice received PBS or IL-22 injections from day +1 after BMT from B6 donors (GVHD, +)  
or B6D2F1 donors (No GVHD, –). (A and B) Clinical GVHD score (A) and survival (B) of mice after BMT (GVHD +: PBS, black circles, n = 18; IL-22, blue circles, n 
= 16; GVHD –, white circles, n = 7). (C−E) Samples were analyzed on day +7 after BMT. (C) Serum REG3γ levels. (D) Ileal tissue Reg3g mRNA expression.  
*P < 0.05, **P < 0.01, unpaired 2-tailed t test (A), 1-way ANOVA (C and D); *P < 0.05, log-rank test (B). (E) H&E (top) staining and REG3γ (bottom) staining 
by immunohistochemistry in ileum from individual mice with or without IL-22 treatment. Naive B6D2F1 mice were used as controls. Images were taken 
with an Olympus BX51 with a ×20 objective. Scale bars: 100 μm. Data are expressed as mean ± SEM.
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Clone Corp.) according to the manufacturer’s protocol. Absorbance was 
measured with a SpectraMax M2 (Molecular Devices), and results were 
calculated with SoftMax Pro version 5.4 software (Molecular Devices).
Western blot. HT-29 cells were treated with human recombi-
nant REG3α protein (5940-RG-050, R&D Systems) (1,000 ng/ml) 
followed by treatment with birinapant (10 nM) and recombinant 
human TNF-α (rhTNF-α; 10 ng/ml) for various time periods (4, 8, 
and 16 hours). Cells were lysed in RIPA buffer containing protease 
and phosphatase inhibitors and sonicated with Bioruptor (Diagen-
ode). Analysis was performed on total cell lysate. Protein was quan-
Figure 6. IL-22 treatment reverses GVHD. B6 mice received 
BM and T cells from C3H.SW donors (GVHD +) treated with 
PBS (black circles) or IL-22 (blue circles) from day +7. As a 
control, mice received BM only (No GVHD, –, white circles). 
(A and B) Clinical GVHD score (A) and survival (B) of mice 
after BMT (PBS, n = 14; IL-22, n = 13; no GVHD, n = 5). Sam-
ples were analyzed on day +10. (C) Serum REG3γ protein. (D) 
Small intestine tissue Reg3g mRNA. *P < 0.05, **P < 0.01, 
unpaired 2-tailed t test (A), 1-way ANOVA (C and D); **P < 
0.01, log-rank test (B). Data are expressed as mean ± SEM.
Figure 7. IL-22 requires REG3γ to reduce GVHD. (A) Survival of WT B6 and B6-Reg3g–/– (KO) mice received PBS or IL-22 injections from day +1 after BMT 
from C3H.SW donors (WT-PBS, black circles, n = 9; WT–IL-22, blue circles, n = 8; KO-PBS, red squares, n = 8; KO–IL-22, blue squares, n = 7). (B) Survival of 
WT B6 and B6-Reg3g–/– (KO) mice received PBS or IL-22 injections from day +1 after BMT from BALB/c donors (WT-PBS, black circles, n = 10; WT–IL-22, blue 
circles, n = 11; KO-PBS, red squares, n = 10; KO–IL-22, blue squares, n = 10). *P < 0.05, log-rank test. (C and D) WT B6 and B6-Reg3g−/− (KO) mice (Lgr5-EGFP+) 
received PBS or IL-22 injections from day +1 after BMT from B6-Ly5.1 donors (GVHD –) or C3H.SW donors (GVHD +). On day +7 after BMT, small intestine 
crypt cells were analyzed by flow cytometry. (C) Quantification of Paneth cells (GVHD –: WT-PBS, empty black circles, n = 8; WT–IL-22, empty blue circles,  
n = 4; KO-PBS, empty red squares, n = 8; KO–IL-22, empty blue squares, n = 6; GVHD +: WT-PBS, filled black circles, n = 13; WT–IL-22, filled blue circles,  
n = 9; KO-PBS, filled red squares, n = 16; KO–IL-22, filled blue squares, n = 10). (D) Quantification of Paneth cells undergoing early apoptosis by annexin V+ 
staining (GVHD –: WT-PBS, empty black circles, n = 5; WT–IL-22, empty blue circles, n = 5; KO-PBS, empty red squares, n = 6; KO–IL-22, empty blue squares, 
n = 5; GVHD +: WT-PBS, filled black circles, n = 7; WT–IL-22, filled blue circles, n = 9; KO-PBS, filled red squares, n = 10; KO–IL-22, filled blue squares, n = 12). 
NS, P > 0.05; *P < 0.05, **P < 0.01, unpaired 2-tailed t test. Data are expressed as mean ± SEM.
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ously (26). Briefly, 5 cm distal ileum was opened longitudinally and 
rinsed in cold PBS, cut into 5-mm pieces, and washed twice with 2 
mM EDTA (Thermo Fisher Scientific) and 1 mM DTT (Thermo 
Fisher Scientific) in serum-free RPMI (MilliporeSigma) for 15 min-
utes at 37°C in a shaker at 150 rpm. Tissues were then washed with 
PBS supplemented with 3% FBS (MilliporeSigma) in a 100-μm cell 
strainer. Tissue was then cut into 1- to 3-mm pieces and incubated 
in a solution containing RPMI, 2% FBS, 3.7 U Liberase (Roche Diag-
nostics), and 400 U DNase I (MilliporeSigma) for 15 minutes in an 
orbital shaker under the same conditions as above. Tissues were sub-
sequently serially filtered through a 70-μm and a 40-μm cell strainer 
using ice-cold PBS, and LPLs were isolated after centrifugation on a 
Percoll gradient (GE Healthcare).
Intestinal crypt isolation and single-cell dissociation. Isolation of 
mouse intestinal crypts and dissociation of cells for analysis by flow 
cytometry were performed as previously described (35). Briefly, 5 cm 
proximal duodenum was opened longitudinally, rinsed in cold PBS, 
and cut into 5-mm pieces. To detach the crypts, small intestine piec-
es were incubated on ice in 10 mM EDTA (Thermo Fisher Scientific) 
for 30 minutes. Intestine was then resuspended vigorously in PBS, 
leading to supernatant enriched in crypts, which was subsequently 
filtered through a 70-μm cell strainer. Following centrifugation of iso-
lated crypts, the pellet was disaggregated into single cells by incuba-
tion for 5 minutes with prewarmed (37°C) 1× TrypLE Express (Gibco, 
Life Technologies) supplemented with 10 μM ROCK inhibitor Y-27632 
tified using Pierce Rapid Gold BCA protein assay kit (Thermo Fisher 
Scientific). Thirty micrograms of lysate was loaded onto NuPAGE 
4%–12% Bis-Tris protein gel or 12% Bis-Tris protein gel, and protein 
was separated by electrophoresis followed by transfer into nitrocel-
lulose membrane. Membranes were blocked for 1 hour at room tem-
perature with tris-buffered saline with tween (TBST) and 5% non-
fat milk and incubated overnight at 4°C with the following primary 
antibodies (Cell Signaling): PARP (9532S), cleaved PARP (5625S), 
caspase-8 (9746S), caspase-3 (29629S), cleaved caspase-3 (9661S), 
and β-actin (5125S). Proteins were detected with Pierce ECL Western 
Blotting Substrate (Thermo Fisher Scientific) or Lumigen ECL Ultra 
(Lumigen) following 1 hour of incubation at room temperature with 
anti-rabbit–HRP (7074S; Cell Signaling) or anti-mouse–HRP (7076S; 
Cell Signaling) antibody.
Apoptosis-induced colorectal epithelial cell viability measurement. 2.5 
× 105 cells of the colorectal cell line HT-29 were cultured in serum- 
deprived DMEM overnight. Human recombinant REG3α protein 
(5940-RG-050, R&D Systems) (10, 100, and 1,000 ng/ml) was add-
ed to culture for 2 hours, and then apoptosis was induced by addi-
tion of birinapant (10 nM) and rhTNF-α (10 ng/ml) to the culture for 
24 hours. Cell viability was measured by CellTiter-Glo 2.0 assay kit 
(Promega) according to the manufacturer’s protocol. Luminescence 
was measured with a SpectraMax M2 (Molecular Devices).
Lamina propria lymphocyte isolation. Lamina propria lympho-
cytes (LPLs) from small intestines were isolated as described previ-
Figure 8. REG3γ protects ISCs from apoptosis. (A–D) WT B6 and B6-Reg3g–/– (KO) mice (Lgr5-EGFP+) received PBS or IL-22 injections from day +1 after BMT 
from B6-Ly5.1 donors (GVHD –) or C3H.SW donors (GVHD +). On day +7 after BMT, small intestine crypt cells were analyzed by flow cytometry, and Reg3g 
mRNA was measured by qPCR. (A) Quantification of ISCs from mice in Figure 7. (B) Quantification of ISCs undergoing early apoptosis by annexin V+ staining 
in the mice from Figure 7. Data are combined from 3 separate experiments. (C) Quantification of EdU+ ISCs in syngeneic recipients (GVHD –: WT-PBS, empty 
black circles, n = 7; WT–IL-22, empty blue circles, n = 4; KO-PBS, empty red squares, n = 9; KO–IL-22, empty blue squares, n = 5), allogeneic recipients (GVHD +: 
WT-PBS, filled black circles, n = 8; WT–IL-22, filled blue circles, n = 9; KO-PBS, filled red squares, n = 13; KO–IL-22, filled blue squares, n = 11), and naive WT 
(downward triangles, n = 5) and KO (upward triangles, n = 5) controls. (D) Correlation of ISCs and Reg3g mRNA expression in WT mice from 2 of the 3 exper-
iments shown in A (n = 25), as calculated by the Pearson correlation coefficient. (E–G) HT-29 cells were cultured with recombinant REG3α protein and apop-
totic stimuli as described in Methods. Data are representative of 3 independent experiments. (E and F) Cell lysates were collected after 16-hour cell culture 
for Western blot analysis. Quantification of cleaved caspase-3 (E) and cleaved caspase-8 (F) expression. (G) Quantification of cell viability by CellTiter-Glo 2.0 
assay after 24-hour cell culture. *P < 0.05, **P < 0.01, unpaired 2-tailed t test. Data are expressed as mean ± SEM. ND, not detectable.
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formed using the R package, and Bray-Curtis compositional distances 
were compared using a Wilcoxon test. All data were tested for normal-
ity through application of the F test with Prism software, and all tests 
were 2-sided. Differences were considered significant when the P value 
was less than 0.05. Data are always presented as mean and SEM for the 
different groups. Unless otherwise specified, all studies for which data 
are presented are representative of at least 2 independent experiments.
Study approval. Study of human blood samples was approved 
by the Icahn School of Medicine at Mount Sinai (IRB 15-0093). The 
mouse research project was approved by the Icahn School of Medicine 
at Mount Sinai (IACUC 2014-0202).
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dihydrochloride (Thermo Fisher Scientific) and 0.5 mM N-acetylcys-
teine (MilliporeSigma).
Flow cytometry. After isolation, LPLs were further incubated with 
Cell Stimulation Cocktail (eBioscience) for 4 hours, and 1 × 106 cells 
were subsequently surface-stained with CD4, CD8, and TCRβ anti-
bodies. For detection of polarized T cell subsets, cells were incubated 
overnight at 4°C in 400 μl of Fix/Perm solution (BD Biosciences), and 
then stained in Perm/Wash buffer (BD Biosciences) with IFN-γ, IL-10, 
and IL-17A antibodies. For detection of Tregs, surface-stained LPLs 
were stained with FoxP3 antibody using the FoxP3/Transcription Fac-
tor Staining Buffer Set (eBioscience). Isolated, dissociated intestinal 
crypt cells were surface-stained with EpCAM, CD45, CD31, TER-119, 
and CD24 antibodies. Apoptotic intestinal crypt cells were detected 
using the Annexin V Apoptosis Detection Kit (eBioscience). DAPI, 
7-aminoactinomycin D, and Fixable Live/Dead Cell Stain Kits (Invi-
trogen) were used for viability staining. All flow cytometry was per-
formed on a FACSCanto or LSR Fortessa, using FACSDiva software 
(all BD Biosciences). Data were analyzed using FlowJo software (Tree 
Star). Full details of all antibodies used are in Supplemental Table 1.
16S sequencing. DNA from fecal pellets of individual mice were 
frozen until DNA was extracted by mechanical disruption (bead- 
beating) in phenol-chloroform. The V4–V5 region of the ribosomal 
RNA gene was amplified, sequenced, and computationally analyzed 
as described (36, 37).
Statistics. Statistical analysis was performed and graphs were gen-
erated using Prism software (GraphPad). Survival curves were plotted 
using Kaplan-Meier estimates and compared using the log-rank test. 
For survival experiments, a sample size of 7 per group provided 80% 
power to detect survival benefit of at least 40% with an α of 0.05. For 
comparison of 2 groups, an unpaired 2-tailed t test for parametric data 
was used. In the case of multiple comparisons, 1-way ANOVA with 
Bonferroni correction was used. Principal component analysis was per-
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